Found: 12
Select item for more details and to access through your institution.
Two‐way regulation of protein expression for identification and validation of on‐target inhibitors of Mycobacterium tuberculosis.
- Published in:
- FASEB Journal, 2022, v. 36, p. N.PAG, doi. 10.1096/fasebj.2022.36.S1.L7723
- By:
- Publication type:
- Article
Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis.
- Published in:
- Molecules, 2022, v. 27, n. 14, p. N.PAG, doi. 10.3390/molecules27144446
- By:
- Publication type:
- Article
Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-31316-6
- By:
- Publication type:
- Article
Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-31157-3
- By:
- Publication type:
- Article
Screening of a Novel Fragment Library with Functional Complexity against <italic>Mycobacterium tuberculosis</italic> InhA.
- Published in:
- ChemMedChem, 2018, v. 13, n. 7, p. 672, doi. 10.1002/cmdc.201700774
- By:
- Publication type:
- Article
New molecular settings to support in vivo anti-malarial assays.
- Published in:
- Malaria Journal, 2016, v. 15, p. 1, doi. 10.1186/s12936-016-1205-x
- By:
- Publication type:
- Article
Repurposing clinically approved cephalosporins for tuberculosis therapy.
- Published in:
- Scientific Reports, 2016, p. 34293, doi. 10.1038/srep34293
- By:
- Publication type:
- Article
N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2- trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
- Published in:
- ChemMedChem, 2016, v. 11, n. 7, p. 687, doi. 10.1002/cmdc.201600020
- By:
- Publication type:
- Article
4-Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween-80 in vitro Dependent Families of Antitubercular Agents with Moderate in vivo Activity.
- Published in:
- ChemMedChem, 2011, v. 6, n. 12, p. 2252, doi. 10.1002/cmdc.201100309
- By:
- Publication type:
- Article
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
- Published in:
- PLoS Neglected Tropical Diseases, 2019, v. 13, n. 1, p. 1, doi. 10.1371/journal.pntd.0007126
- By:
- Publication type:
- Article
Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.
- Published in:
- PLoS ONE, 2015, v. 10, n. 12, p. 1, doi. 10.1371/journal.pone.0142293
- By:
- Publication type:
- Article